Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• EPHESUSAn independent statistical analysis of the EPHESUS trial, a 6000-patient survey of under-treatment of hypercholesterolemia and appropriate lipid-lowering therapy in patients with hyperlipidemias.n = 6,000NCT02608645
• ePHex-OLEIndependent statistical analysis of An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 22NCT03938272
• EQUIPED-ADRDIndependent statistical analysis of Enhanced Quality in Primary Care for Elders With Diabetes and Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 355NCT03723707
• Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: Complete Statistical AnalysisIndependent statistical analysis of Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 20NCT02018627
• Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 15NCT00383760
• Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 74NCT00334893
• Ertugliflozin: Cardioprotective Effects on Epicardial Fat: Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin: Cardioprotective Effects on Epicardial Fat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04167761).Phase EARLY_1Results postedn = 61NCT04167761
• Estrogen and Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Estrogen and Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436992).Phase NAResults postedn = 143NCT03436992
• Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 11NCT02228460
• Evaluating Telementoring for CHW-centered Diabetes Initiatives: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Telementoring for CHW-centered Diabetes Initiatives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04835493).Phase NAResults postedn = 320NCT04835493
• Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 33NCT00847730
• Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 1,754NCT04033640
• Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 250NCT00741390
• Evaluation of DIDGET TM World Reports: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of DIDGET TM World Reports: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923975).Phase NAResults postedn = 51NCT00923975
• Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 30NCT01561976
• Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 39NCT00762229
• Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 2,230NCT02666664
• Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 769NCT00925600
• Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 16NCT02692495
• Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 4NCT05351164
• Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 32NCT01692938
• Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 217NCT03317444
• Evaluation of Vitamin D Requirements During Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Vitamin D Requirements During Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00292591).Phase 3Results postedn = 501NCT00292591
• EVOLVEIndependent statistical analysis of Epanova® for Lowering Very High Triglycerides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01242527).Phase 2/3Results postedn = 399NCT01242527
• EVOLVEIIIndependent statistical analysis of Epanova® for Lowering Very High Triglycerides II (EVOLVE II): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02009865).Phase 3Results postedn = 379NCT02009865
• EXAMINERIndependent statistical analysis of A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 247NCT01896479
• Exenatide in Extreme Pediatric Obesity: Complete Statistical AnalysisIndependent statistical analysis of Exenatide in Extreme Pediatric Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01237197).Phase 2Results postedn = 26NCT01237197
• Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03355469).Phase 2/3Results postedn = 91NCT03355469
• EXSCELA detailed independent statistical analysis of EXSCEL, the phase 3 trial of exenatide once weekly versus placebo in patients with type 2 diabetes mellitus, including its randomized design, time-to-event endpoints, Cox models,…Phase 3Results postedn = 14,752NCT01144338
• EXTENDIndependent statistical analysis of Expanding Technology-Enabled Nurse Delivered Chronic Disease Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05120544).Phase NAResults postedn = 220NCT05120544
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: Complete Statistical AnalysisIndependent statistical analysis of Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02720536).Phase 3Results postedn = 53NCT02720536
• Extension Study of MYL-1701P-3001 for Safety and Efficacy: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of MYL-1701P-3001 for Safety and Efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04674800).Phase 3Results postedn = 52NCT04674800
• Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 19NCT00171951
• Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 4,550NCT00523341
• Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects: Complete Statistical AnalysisIndependent statistical analysis of Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects: primary endpoint results, effect estimate…Phase 4Results postedn = 8NCT02750930
• EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 298NCT03643705
• FAIR-HFAn independent statistical analysis of the randomized phase 3 FAIR-HF trial evaluating ferric carboxymaltose versus normal saline in patients with chronic heart failure and iron deficiency.Phase 3n = 456NCT00520780
• FAMEIndependent statistical analysis of Females, Aging, Metabolism, and Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712230).Phase NAResults postedn = 47NCT01712230
• Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 56NCT05523362
• Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 3NCT05911243
• Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 21NCT00582205
• Feasibility Trial Using an Inpatient Insulin Dosing Calculator: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Trial Using an Inpatient Insulin Dosing Calculator: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06206525).Phase NAResults postedn = 38NCT06206525
• Fenofibrate Treatment in SCI: Complete Statistical AnalysisIndependent statistical analysis of Fenofibrate Treatment in SCI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02455336).Phase 2/3Results postedn = 23NCT02455336
• FermCarbIndependent statistical analysis of Effect of Fermentable Carbohydrate on Glucose Homeostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01841073).Phase NAResults postedn = 44NCT01841073
• FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00999037).Phase NAResults postedn = 18NCT00999037
• FIDELIO-DKDIndependent statistical analysis of Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 5,734NCT02540993
• FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.Phase 3Results postedn = 7,352NCT02545049
• FINANCE-DMIndependent statistical analysis of Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04203173).Phase NAResults postedn = 450NCT04203173
• First HeroesIndependent statistical analysis of First Heroes: Engaging Fathers in the First 1000 Days: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04477577).Phase NAResults postedn = 657NCT04477577
• First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: Complete Statistical AnalysisIndependent statistical analysis of First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: primary endpoint…Phase 4Results postedn = 458NCT01419249

← All therapeutic areas